Full-Time

Unified Communication Architect

Updated on 6/12/2025

Gilead Sciences

Gilead Sciences

10,001+ employees

Develops and commercializes biopharmaceuticals for various diseases

Compensation Overview

$169.3k - $219.1k/yr

+ Bonus + Stock-based long-term incentives

Senior, Expert

Company Historically Provides H1B Sponsorship

San Mateo, CA, USA

Category
IT Project Management
System Administration
IT & Security
Requirements
  • Bachelor’s degree in related discipline and ten years of related experience; or
  • Master’s degree in related discipline and ten years of related experience; or
  • PhD degree in related discipline and eight years of related experience; or
  • Equivalent combination of education and experience.
  • Proven experience developing a strategy and roadmap for modernizing communications and collaborations technologies and experiences across the entire organization.
  • Demonstrated thought-leader, capable of identifying and understanding technology trends and applying them to Gilead Sciences’ needs and use cases.
  • Experience managing an application portfolio with a diverse set of unified communications solutions, including but not limited to phone services, fax services, IVR configurations, auto attendants, and conferencing solutions.
  • Proven track record of taking ownership and successfully delivering results in a fast-paced, dynamic environment.
  • Experience driving enterprise-wide technology adoption while understanding and adapting communications solutions to meet different needs across the organization.
  • Experience with diverse technologies such as Zoom, Microsoft Teams, WebEx, CUCM, VC, SBCs & traditional telephony equipment.
  • Experience managing relationships with telecommunications vendors.
  • Comprehensive knowledge of unified communications and digital collaboration applications in enterprise organizations.
Responsibilities
  • Develop and maintain telephony and Unified Communications standards to meet the demands of a global science-oriented organization.
  • Consult with key stakeholders about our telephony and Unified Communications capabilities and standards.
  • Design voice, telephony and Unified Communications and the best practices surrounding their implementation.
  • Establish and uphold quality and maintenance standards for the worldwide deployment and upkeep of global Unified Communication technology.
  • Construct and maintain an efficient laboratory environment to assess incremental updates and evaluate novel tools and technologies.
  • Engage in a high-performance delivery and operations team, ensuring an exemplary employee experience across conferencing, video, streaming, and voice services.
  • Identify and implement communication solutions and services that cater to the organization's expanding needs and growth.
  • Drive a transformation in employee work patterns and connections through innovative meeting room designs, physical spaces, and user-friendly devices.
  • Explore emerging technological trends that could enhance workplace dynamics, evaluating their potential through continuous proof of concepts and pilot projects.
  • Collaborate closely with IT counterparts, Facilities, IT Security, business stakeholders, partners, vendors, and managed service providers to uphold an exceptional user experience with telephony, Unified Communications systems, equipment, and spaces.

Gilead Sciences is a biopharmaceutical company that develops and sells medicines for various serious health conditions, including HIV/AIDS, liver diseases, cancer, inflammatory and respiratory diseases, and cardiovascular issues. The company focuses on extensive research and development to create new therapies, which are then approved by regulatory authorities before being marketed to healthcare providers and pharmacies. Gilead stands out from its competitors by investing heavily in R&D and forming strategic partnerships, such as with SAP Ariba, to improve its supply chain and manufacturing processes. The company's goal is to enhance health equity and access to care globally, working with communities to ensure that its medicines reach those in need.

Company Size

10,001+

Company Stage

IPO

Headquarters

Foster City, California

Founded

1987

Simplify Jobs

Simplify's Take

What believers are saying

  • Gilead's U.S. investment creates significant economic value and job opportunities.
  • AI technologies could lead to faster drug development cycles for Gilead.
  • Top five ranking in Most JUST list enhances Gilead's reputation and stakeholder trust.

What critics are saying

  • $202 million settlement may damage Gilead's reputation and increase regulatory scrutiny.
  • Layoffs of 150 employees, including senior management, may disrupt operations and morale.
  • Rise of AI drug discovery companies poses a competitive threat to Gilead's R&D model.

What makes Gilead Sciences unique

  • Gilead's oncology navigation grant program enhances cancer care through innovative solutions.
  • $11 billion investment in U.S. manufacturing boosts operational capabilities and innovation pipeline.
  • AI-driven drug discovery enhances R&D efficiency and cost-effectiveness for Gilead.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Paid family time off and paid parental time off

Generous 401(k) contribution matching

Comprehensive medical plans that cover both physical and mental healthcare

Global Wellbeing Reimbursement

Time Off

Global Volunteer Day

Giving Together Program

Employee Support Programs

Flexible Work Options

Company News

PR Newswire
Jun 1st, 2025
The Academy Of Oncology Nurse Patient Navigators And Gilead Sciences Partner To Launch Oncology Navigation Grant Program

GAINESVILLE, Fla., June 1, 2025 /PRNewswire/ -- The Academy of Oncology Nurse & Patient Navigators (AONN+) is proud to announce the launch of a groundbreaking grant program in partnership with Gilead Sciences aimed at advancing the field of oncology navigation and enhancing patient outcomes within the healthcare setting. This initiative is designed to support the creation, enhancement, and expansion of innovative tools that optimize efficiency and elevate the critical role of oncology navigators.Following the AONN+ call for grant submissions in April, healthcare leaders across the country responded with creative applications, software solution ideas and healthcare system improvements. AONN+ looks to announce the recipients of the award, valued up to $500,000, in June with project work to begin in the July time frame. The AONN+ grant application process and implementation support for awardees also included help from Amplity, AONN+'s association management partner and strategic collaborator."Through this funding mechanism, AONN+ and Gilead are committed to addressing persistent challenges in cancer care by empowering navigators to play a pivotal role in improving patient access to navigation services, removing barriers to cancer care, and supporting treatment adherence," says Candice Roth, MSN, RN, CENP, Executive Director, AONN+. "Navigator utilization continues to present significant opportunities for optimizing patient outcomes, and this program seeks to provide impactful solutions that directly tie proposed tools to measurable improvements in patient care.""As part of Gilead's Community Cancer Collective, we are proud to partner with AONN+ on this exciting initiative in support of the oncology community," said Darren Tayama, M.D., Vice President, US Medical Affairs, Oncology. "Together, AONN+ and Gilead are advancing the future of cancer care through innovative solutions in oncology navigation."About the Academy of Oncology Nurse & Patient Navigators , Inc

Labiotech
May 27th, 2025
Interleukin Therapeutics: 9 Companies To Follow In 2025

Newsletter Signup - Under Article / In Page"*" indicates required fields Interleukins — a group of signaling proteins that help immune cells communicate — have long been recognized as powerful tools in modulating immune responses. Over the years, companies have explored interleukin as treatments for cancer, autoimmune conditions, and inflammatory diseases. But while some interleukin-based drugs have reached the market, many early attempts were held back by toxicity and a lack of precision.Today, that’s starting to change. Advances in protein engineering, mRNA technology, and cell-targeted delivery have opened up new ways to harness interleukins more safely and effectively. Big pharma is already active in this space, but a growing number of smaller biotech companies are helping to push the field forward.In this list, we take a look at some of the most interesting biotech companies and emerging players developing interleukin therapeutics. Ankyra Therapeutics Headquarters: Cambridge, MassachusettsFounded: 2019Recent News: Presented preliminary phase 1 clinical data for ANK-101 at the AACR Annual MeetingAnkyra Therapeutics is a biotech developing anchored immunotherapies aimed at enhancing the therapeutic window of cytokine-based treatments. The company’s lead candidate, ANK-101 (tolododekin alfa), is an interleukin-12 (IL-12) cytokine anchored to aluminum hydroxide, designed for localized delivery to tumors.ANK-101 employs Ankyra’s proprietary Anchored Immunotherapy Platform, which involves fusing IL-12 with an alum-binding peptide, allowing the complex to bind to aluminum hydroxide (Alhydrogel)

Fierce Pharma
May 8th, 2025
Gilead tees up $11B in new US manufacturing, R&D investments

This time it's Gilead coming to the table with a fresh $11 billion in hand to spend across its manufacturing and research centers in the U.S.

Gilead Sciences
May 7th, 2025
Gilead U.S. Investment to Create $43 Billion in Value to U.S. Economy

Gilead to invest $32 billion in U.S. manufacturing and R&D through 2030 and create more than 3,000 direct and indirect jobs by 2028

Constantine Cannon
May 5th, 2025
Gilead Pays $202M to Settle False Claims Act Kickback Charges

On April 29, the Department of Justice (DOJ) announced that California-based pharmaceutical giant Gilead Sciences agreed to pay $202 million to settle charges of violating the False Claims Act and Anti-Kickback Statute.